# Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

> **NCT03380962** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Stanley Jordan, MD** · enrollment: 20 (actual)

## Conditions studied

- Kidney Failure, Chronic
- End-Stage Renal Disease
- Transplant Glomerulopathy
- Transplant;Failure,Kidney
- Kidney Transplant Failure and Rejection
- Antibody-mediated Rejection
- Kidney Transplant; Complications

## Interventions

- **DRUG:** Clazakizumab

## Key facts

- **NCT ID:** NCT03380962
- **Lead sponsor:** Stanley Jordan, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-02-27
- **Primary completion:** 2025-08-30
- **Final completion:** 2025-08-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03380962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03380962, "Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03380962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*